Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Lenvatinib + Pembrolizumab & Renal Cell Carcinoma (RCC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Regulatory status:

In the context of Lenvatinib + Pembrolizumab & Renal Cell Carcinoma (RCC), Lenvatinib + Pembrolizumab is approved by both FDA and EMA as a first‑line systemic treatment option for advanced / metastatic Renal Cell Carcinoma (RCC) (1, 2, 3, 4)

Clinical data:

In the randomized clinical phase III trial, identified as NCT02811861 (CLEAR/KEYNOTE‑581),

it was discovered that the combination of Lenvatinib + Pembrolizumab resulted in significantly longer progression-free survival and overall survival compared to [sunitinib](brain://OACiQ5…

References (Sources)

Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer
Garces et al. 2019
Review
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study
Motzer et al. 2024 Eur Urol 86(1): 4-9
Combined use of pembrolizumab and lenvatinib: A review
Eisinger & Muluneh 2023 J Oncol Pharm Pract 29(6): 1461-1466
Review
First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape
Gulati et al. 2022 The Oncologist 27: 125-134
Review
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Motzer et al. 2021 N Engl J Med 384:1289-1300
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Motzer et al. 2024 J Clin Oncol 42: 1222-1228
New approaches to first-line treatment of advanced renal cell carcinoma
George et al. 2021a Ther Adv Med Oncol 13: 17588359211034708
Review

AI Chat

7/1/2026

Chat with our artificial intelligence: